Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 03, 2021 at 11:20 am
Share
Nanjing Hicin Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 316.902 million compared to CNY 375.842 million a year ago. Operating income was CNY 22.647 million compared to CNY 42.269 million a year ago. Net income was CNY 21.136 million compared to CNY 36.485 million a year ago. Basic earnings per share from continuing operations was CNY 0.1761 compared to CNY 0.304 a year ago.
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
NANJING HICIN PHARMACEUTICAL CO., LTD. 
